Lillie James Woodruff 4

What Happened Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics (MPLT), reported multiple open‑market sales of company stock between July 15–17, 2026. In total she disposed of 18,267 shares for aggregate proceeds of approximately $673,636. Individual reported transactions include:

• 7/15/2026: 2,238 shares @ $36.00 = $80,568
• 7/15/2026: 5,393 shares @ $36.99 = $199,487
• 7/15/2026: 12 shares @ $37.54 = $450
• 7/16/2026: 5,009 shares @ $36.45 = $182,578
• 7/16/2026: 3,526 shares @ $37.26 = $131,379
• 7/16/2026: 12 shares @ $37.96 = $456
• 7/17/2026: 2,077 shares @ $37.90 = $78,718

These were sales (not purchases); at least one lot was a non‑discretionary "sell‑to‑cover" to satisfy tax withholding on vested restricted stock units (RSUs), per the filing footnote.

Key Details

• Transaction dates: July 15–17, 2026; filing date: July 17, 2026 (Form 4 accession 0001728746-26-000012).
• Total shares sold: 18,267; total reported proceeds: ~$673,636.
• Price range across lots: weighted average prices reported, with component trade prices ranging roughly from $35.5338 up to $37.925 (see footnotes F2–F6 for exact ranges).
• Notable footnotes:
  • F1: One lot represents shares sold to satisfy statutory tax withholding on RSU vesting (sell‑to‑cover — non‑discretionary).
  • F2–F6: Indicate weighted‑average prices and provide the per‑trade price ranges for multiple executions; the filer offers to provide exact per‑price breakdowns on request.
• Shares owned after the transactions: not specified in the summary provided (check the full Form 4 for post‑transaction holdings).
• Filing timeliness: Form filed July 17, 2026 covering trades through July 17; filing does not appear to be late.

Context

• Sell‑to‑cover transactions are routine tax‑related sales tied to RSU vesting and do not necessarily indicate a change in insider sentiment.
• These were open‑market sales by an executive officer (CSO); purchases by insiders are generally viewed as stronger signals of confidence, while routine sales (especially sell‑to‑cover) are common.
• If you want the exact number of shares sold at each execution price within the weighted‑average ranges, the filer has pledged to provide that detail upon request to the issuer, any security holder, or the SEC staff.